Dernières nouvelles pour Zimmer Biomet Holdings (NYSE:ZBH) Stock

Zimmer Biomet Holdings

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings Inc

Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) underwent analysis by 21 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Zimmer Biomet Holdings and provided 12-month price targets. The average target is $121.76, accompanied by a high estimate of $145.00 and a low estimate of $107.00. This current average has decreased by 4.31% from the previous average price target of $127.24. 
<img src="https://www.benzinga.com/files/images/story/2024/1730754009_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Zimmer Biomet Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$117.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$117.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$123.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$126.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$110.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$112.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$119.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$117.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>In-Line</td>
<td>$113.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$120.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$128.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Lowers</td>
<td>Sell</td>
<td>$107.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$113.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$155.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Zimmer Biomet Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Zimmer Biomet Holdings compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Zimmer Biomet Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Zimmer Biomet Holdings's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ZBH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Zimmer Biomet Holdings analyst ratings.</a>
<h2>Discovering Zimmer Biomet Holdings: A Closer Look</h2>
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
<h3>Understanding the Numbers: Zimmer Biomet Holdings's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Zimmer Biomet Holdings showcased positive performance, achieving a revenue growth rate of 4.03% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 13.66%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Zimmer Biomet Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.98%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Zimmer Biomet Holdings's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.15%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Zimmer Biomet Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.53.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What 21 Analyst Ratings Have To Say About Zimmer Biomet Holdings

RBC Capital analyst Shagun Singh maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Outperform and raises the price target from $120 to $125.

News

Price Target

RBC Capital Maintains Outperform on Zimmer Biomet Holdings, Raises Price Target to $125

Truist Securities analyst Richard Newitter maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Hold and raises the price target from $112 to $117.

Truist Securities Maintains Hold on Zimmer Biomet Holdings, Raises Price Target to $117

License Provides Exclusive Commercialization Rights for US Distribution and Certain OUS Markets Agreement expected to boost NeuroOne sales revenue and profitability
EDEN PRAIRIE, Minn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the execution of an amendment to its existing distribution agreement with Zimmer Biomet that will provide Zimmer Biomet with certain exclusive rights to distribute NeuroOne's OneRF&#x2122; Ablation System for use in the brain.

Biotech

General

NMTC

NeuroOne Announces Expansion Of Existing Distribution Agreement With Zimmer Biomet For Commercialization Of OneRF Ablation System; NeuroOne Will Receive An Upfront Payment Of $3M; License Provides Exclusive Commercialization Rights For U.S. Distribution And Certain OUS Markets

Wells Fargo analyst Larry Biegelsen maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Equal-Weight and raises the price target from $110 to $117.

Wells Fargo Maintains Equal-Weight on Zimmer Biomet Holdings, Raises Price Target to $117

Zimmer Biomet Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) short percent of float has fallen 14.44% since its last report. The company recently reported that it has 5.75 million shares sold short, which is 3.2% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.12 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Zimmer Biomet Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730380519_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zimmer Biomet Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Zimmer Biomet Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Zimmer Biomet Holdings's peer group average for short interest as a percentage of float is 4.32%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

(ZBH) - Analyzing Zimmer Biomet Holdings's Short Interest

Needham analyst Mike Matson reiterates Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Zimmer Biomet Holdings

On Wednesday, Zimmer Biomet Holdings, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) reported third-quarter adjusted EPS of $1.74, up from $1.65 a year ago, in line <a href="https://www.benzinga.com/calendars/earnings">with the Street estimates.</a>
The orthopedic giant reported sales of $1.82 billion, up 4% on a reported basis (+4.1% on constant currency), beating the <a href="https://www.benzinga.com/pressreleases/24/10/n41619991/zimmer-biomet-announces-third-quarter-2024-financial-results">consensus of $1.79 billion</a>.
Knee product sales increased 5.5% to $745.1 million, and hip product sales 3.5% (+3.7% on constant currency) to $481.5 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40927367/zimmer-biomet-to-stop-selling-cpt-hip-implant-system-by-end-of-2024-due-to-high-fracture-risks" rel="noreferrer noopener">Zimmer Biomet To Stop Selling CPT Hip Implant System By End Of 2024 Due To High Fracture Risks</a>
Sports Medicine products generated sales of $454.2 million, up 7.3%.
&#8220;We are pleased with the strong performance we delivered in the third quarter, despite our ERP implementation challenges,&#8221; said Ivan Tornos, Zimmer Biomet&#8217;s President and Chief Executive Officer. &#8220;
Operating margin remained unchanged at around 15%.
Net profit increased from $162.8 million to $249.2 million.
Guidance: Zimmer Biomet adjusted its 2024 adjusted EPS outlook from $8.00-$8.15 to $7.95-$8.05 compared to the consensus of $7.95.
The Warsaw, Indiana-based company expects 2024 revenue growth of 3.5%-4% versus the prior guidance range of 4%-5%.
On Monday, Zimmer Biomet unveiled its plans for the broad commercial launch of the Z1 Femoral Hip System (Z1 System) for total hip arthroplasty at the 2024 annual American Association of Hip <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41570498/zimmer-biomet-to-debut-new-z1-femoral-hip-system-and-clinical-data-on-g7-acetabular-system-at-2024" rel="noreferrer noopener">and Knee Surgeons meeting</a>.
The highly-anticipated Z1 Femoral Hip System, a triple-taper femoral system, pairs with the company&#8217;s G7&nbsp;Acetabular System&nbsp;to provide surgeons with a total hip arthroplasty solution.
Price Action: ZBH stock is up 4.63% at $108.69 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41627252/fortive-q3-revenue-miss-eps-beat-revises-fy24-guidance-amid-strategic-split-plans" target="_blank" rel="noreferrer noopener">Fortive Q3: Revenue Miss, EPS Beat, Revises FY24 Guidance Amid Strategic Split Plans</a></li>
</ul>

Earnings

Guidance

Health Care

Movers

Orthopedic Implant Maker Zimmer Biomet Reports Better-Than-Expected Q3 Earnings, Updates Annual Forecasts

WIIM

Zimmer Biomet Holdings shares are trading higher after the company reported better-than-expected Q3 sales results.

Financial Guidance
The Company is updating its full-year 2024 financial guidance to reduce and narrow its previous projected ranges for revenue growth and adjusted1 diluted EPS:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2" rowspan="1">Projected Year Ending December 31, 2024</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Previous Guidance</td>
<td colspan="1" rowspan="1">Updated Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">2024 Reported Revenue Change</td>
<td colspan="1" rowspan="1">4.0% - 5.0%</td>
<td colspan="1" rowspan="1">3.5% - 4.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Foreign Currency Exchange Impact</td>
<td colspan="1" rowspan="1">(1.0)&nbsp;%</td>
<td colspan="1" rowspan="1">(0.75)&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">2024 Constant Currency Revenue Change</td>
<td colspan="1" rowspan="1">5.0% - 6.0%</td>
<td colspan="1" rowspan="1">4.25% - 4.75%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Diluted EPS(1)</td>
<td colspan="1" rowspan="1">$8.00 - $8.15</td>
<td colspan="1" rowspan="1">$7.95 - $8.05</td>
</tr>
</tbody>
</table>
</figure>

Zimmer Biomet Lowers FY24 Outlook: Adj EPS from $8.00-$8.15 to $7.95-$8.05 vs $7.95 Est, Revenue Growth Of 3.5%-4% (4%-5% Prior)

Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) reported quarterly earnings of $1.74 per share which met the analyst consensus estimate. This is a 5.45 percent increase over earnings of $1.65 per share from the same period last year. The company reported quarterly sales of $1.824 billion which beat the analyst consensus estimate of $1.795 billion by 1.59 percent. This is a 3.99 percent increase over sales of $1.754 billion the same period last year.

Earnings Beats

Zimmer Biomet Q3 2024 Adj. EPS $1.74, Inline, Sales $1.824B Beat $1.795B Estimate

Zimmer Biomet Holdings, Inc.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/zbh#NYSE">ZBH</a>) is scheduled to report third-quarter 2024 results on Oct. 30, before market open.
In the last reported quarter, the company&#39;s earnings of $2.01 beat the Zacks Consensus Estimate by 1.5%. ZBH beat on earnings in each of the trailing four quarters, the average surprise being 2.84%.
<h2>ZBH&#39;s Q3 Estimates</h2>
The Zacks Consensus Estimate for revenues is pegged at $1.81 billion, suggesting a 3.3% rise from the year-ago reported figure.
The Zacks Consensus Estimate for earnings is pinned at $1.75 per share, indicating a 6.1% improvement from the year-ago reported numbers.
<h2>Estimate Revision Trend Ahead of ZBH&#39;s Q3 Earnings</h2>
The Zacks Consensus Estimate for earnings has moved south 1.1%&nbsp; to $1.75 per share in the past 30 days.
Let&#39;s briefly look at how things might have shaped up for this MedTech major in the to-be-reported quarter.
<h2>Factors at Play</h2>
Zimmer Biomet is likely to have experienced strong growth in the&nbsp;third quarter on the back of strong performance from its business segments.
The Hip business is expected to have witnessed growth due to the company&#39;s comprehensive suite of solutions in navigation in direct anterior stems and surgical impactors.
While this business lagged&nbsp;the broader market during the second quarter due to key portfolio gaps, the company has made significant progress with new product introductions. During the same quarter, Zimmer Biomet launched the&nbsp;surgical impactor HAMMR, whose adoption has been great so far. Additionally, during the&nbsp;third-quarter, the company entered into a definitive agreement to acquire OrthoGrid Systems, Inc. The acquisition includes OrthoGrid&#39;s AI-powered, fluoroscopy-based surgical assistance platform&nbsp;Hip AI, as well as two additional FDA-cleared orthopedic applications and over 40 patents.
Outside the United States, ZBH expects to launch a second generation of hip posterior robotics. Banking on these developments, the company is expected to report a strong revenue increase within this category in the third quarter.
Within the Knees business, the company faced some challenges from a supply standpoint. These are high ASP cases.
<h2>Zimmer Biomet Holdings, Inc. Price and EPS Surprise</h2>
<div class="chart_embed"><img alt="Zimmer Biomet Holdings, Inc. Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/50/1729087518.png" style="height:263px; width:544px" title="" />
Zimmer Biomet Holdings, Inc. price-eps-surprise | Zimmer Biomet Holdings, Inc. Quote
</div>
Although this business in the United States was softer than expected, the company delivered knee growth of 5% year over year in the second quarter. We expect this growth trend to have continued in the third quarter as well.&nbsp;
The company expects to launch two different ROSA for knees in the coming three to eight quarters. In addition to ROSA, Zimmer Biomet has a partnership with THINK Surgical for TMINI &mdash; a&nbsp;miniature handheld robotic system for total knee arthroplasty. TMINI was supposed to be released in the second half of 2024. These developments might have had a positive impact on the company&#39;s third-quarter top-line performance.
In the second quarter, the S.E.T business grew mid-single digits, led by key focus areas of CMFT, upper extremities and sports growing on average high-single digits. The second quarter of 2024 was the third quarter in a row to experience such growth. Every single business within S.E.T. grew for the first time in the&nbsp;second quarter. We expect this trend to have continued in the third quarter as well.
<h2>What Our Model Suggests for ZBH</h2>
Per our proven model, a stock with a positive&nbsp;Earnings ESP&nbsp;and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a higher chance of beating estimates. This is not the case here, as you can see below.
Earnings ESP: Zimmer Biomet has an Earnings ESP of -1.65%%.
Zacks Rank: The company currently carries a Zacks Rank #4 (Strong).
<h2>Stocks Worth a Look</h2>
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle.
Atea Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avir#NASDAQ">AVIR</a>) has an Earnings ESP of +13.13% and a Zacks Rank #1 at present.
The company is expected to release third-quarter 2024 results on Nov. 13. AVIR&#39;s earnings surpassed estimates in two of the trailing four quarters and missed in the other two, the average surprise being 5.23%.
RadNet&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdnt#NASDAQ">RDNT</a>)&nbsp;has an Earnings ESP of +20.00% and a Zacks Rank #2 at present. The company is expected to release third-quarter 2024 results on Nov. 13.
RDNT&#39;s earnings surpassed estimates in three of the trailing four quarters and broke even once, the average surprise being 98.23%. The Zacks Consensus Estimate for RadNet&#39;s third-quarter EPS is expected to increase 21.4% from the year-ago quarter&#39;s reported numbers.
TransMedics Group&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) has an Earnings ESP of +26.63% and a Zacks Rank #3 at present. The company is likely to release third-quarter 2024 results on Nov. 4. The Zacks Consensus Estimate for the company&#39;s third-quarter EPS implies a surge of 333.3% from the year-ago quarter&#39;s reported figure.
<a href="https://www.zacks.com/stock/news/2351618/zbh-gears-up-for-q3-earnings-what-lies-ahead-for-the-stock?cid=CS-BENZ-FT-analyst_blog|earnings_preview-2351618">To read this article on Zacks.com click here.</a>

Large Cap

Mid Cap

Penny Stocks

Small Cap

Markets

AVIR

RDNT

TMDX

ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Scotiabank raised FirstService Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSV#NASDAQ">FSV</a>) price target from $190 to $200. Scotiabank analyst Himanshu Gupta maintained a Sector Perform rating. FirstService shares closed at $184.78 on Monday. <a href="https://www.benzinga.com/quote/FSV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>DA Davidson boosted the price target for ACI Worldwide, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIW#NASDAQ">ACIW</a>) from $52 to $57. DA Davidson analyst Peter Heckmann maintained a Buy rating. ACI Worldwide shares closed at $52.66 on Monday. <a href="https://www.benzinga.com/quote/ACIW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS cut the price target for Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) from $105 to $103. UBS analyst Faham Baig maintained a Sell rating. Philip Morris shares closed at $120.08 on Monday. <a href="https://www.benzinga.com/quote/PM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo raised The Sherwin-Williams Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) price target from $350 to $400. Wells Fargo analyst Michael Sison maintained an Equal-Weight rating. Sherwin-Williams shares closed at $384.16 on Monday. <a href="https://www.benzinga.com/quote/SHW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital raised S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) price target from $537 to $589. BMO Capital analyst Jeffrey Silber maintained an Outperform rating. S&amp;P Global shares closed at $527.52 on Monday. <a href="https://www.benzinga.com/quote/SPGI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities raised McDonald&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) price target from $295 to $350. Truist Securities analyst Jake Bartlett maintained a Buy rating. McDonald&#8217;s shares closed at $309.84 on Monday. <a href="https://www.benzinga.com/quote/MCD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group raised the price target for Brinker International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) from $69 to $90. Evercore ISI Group analyst David Palmer maintained an In-Line rating. Brinker settled at $87.70 on Monday. <a href="https://www.benzinga.com/quote/EAT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler raised Viper Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>) price target from $57 to $61. Piper Sandler analyst Mark Lear maintained an Overweight rating. Viper Energy shares closed at $51.97 on Monday. <a href="https://www.benzinga.com/quote/VNOM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer cut the price target for Zimmer Biomet Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) from $145 to $135. Oppenheimer analyst Steven Lichtman maintained an Outperform rating. Zimmer Biomet shares closed at $104.83 on Monday. <a href="https://www.benzinga.com/quote/ZBH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen cut SM Energy Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SM#NYSE">SM</a>) price target from $64 to $60. TD Cowen analyst Gabe Daoud upgraded the stock from Hold to Buy. SM Energy shares closed at $44.62 on Monday. <a href="https://www.benzinga.com/quote/SM/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying MCD stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="505" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/15115425/image-119-1024x505.png" alt="" class="wp-image-596539" style="width:681px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/15115425/image-119-1024x505.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/15115425/image-119-300x148.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/15115425/image-119-768x379.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/15115425/image-119.png 1331w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41331971/how-to-earn-500-a-month-from-morgan-stanley-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Morgan Stanley Stock Ahead Of Q3 Earnings</a></li>
</ul>

ACIW

SPGI

VNOM

McDonald's To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Tuesday

Oppenheimer analyst Steven Lichtman maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Outperform and lowers the price target from $145 to $135.

Oppenheimer Maintains Outperform on Zimmer Biomet Holdings, Lowers Price Target to $135

Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) underwent analysis by 17 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $121.35, a high estimate of $145.00, and a low estimate of $107.00. This current average has decreased by 5.59% from the previous average price target of $128.53. 
<img src="https://www.benzinga.com/files/images/story/2024/1728936032_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Zimmer Biomet Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$123.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$126.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$110.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$112.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$119.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$117.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>In-Line</td>
<td>$113.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$120.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$128.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Lowers</td>
<td>Sell</td>
<td>$107.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$113.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$155.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Zimmer Biomet Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Zimmer Biomet Holdings compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Zimmer Biomet Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ZBH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Zimmer Biomet Holdings analyst ratings.</a>
<h2>Delving into Zimmer Biomet Holdings's Background</h2>
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
<h3>Zimmer Biomet Holdings's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Zimmer Biomet Holdings showcased positive performance, achieving a revenue growth rate of 3.87% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Zimmer Biomet Holdings's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 12.5% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Zimmer Biomet Holdings's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.92%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.13%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Zimmer Biomet Holdings's debt-to-equity ratio is below the industry average at 0.46, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Zimmer Biomet Holdings's Future

Raymond James analyst Jayson Bedford maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Outperform and lowers the price target from $128 to $123.

Raymond James Maintains Outperform on Zimmer Biomet Holdings, Lowers Price Target to $123

Zimmer Biomet Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) short percent of float has risen 15.79% since its last report. The company recently reported that it has 6.71 million shares sold short, which is 3.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.17 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Zimmer Biomet Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728674114_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zimmer Biomet Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Zimmer Biomet Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Zimmer Biomet Holdings's peer group average for short interest as a percentage of float is 4.66%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Zimmer Biomet Holdings's Recent Short Interest

RBC Capital analyst Shagun Singh maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Outperform and lowers the price target from $130 to $120.

RBC Capital Maintains Outperform on Zimmer Biomet Holdings, Lowers Price Target to $120

BTIG analyst Ryan Zimmerman maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Buy and lowers the price target from $134 to $126.

BTIG Maintains Buy on Zimmer Biomet Holdings, Lowers Price Target to $126

Evercore ISI Group analyst Vijay Kumar maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a In-Line and lowers the price target from $113 to $110.

Evercore ISI Group Maintains In-Line on Zimmer Biomet Holdings, Lowers Price Target to $110

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Zimmer Biomet Holdings (ZBH – Research Report) today and set a price target of $...

RBC Capital Reaffirms Their Buy Rating on Zimmer Biomet Holdings (ZBH)

RBC Capital raised the firm's price target on Zimmer Biomet (ZBH) to $125 from $120 and keeps an Outperform rating on the shares after its Q3 resul...

Zimmer Biomet price target raised to $125 from $120 at RBC Capital

New study reveals another benefit in using Novo Nordisk's Wegovy in obesity

In a report released yesterday, Richard Newitter from Truist Financial maintained a Hold rating on Zimmer Biomet Holdings (ZBH – Research Report), ...

Truist Financial Sticks to Their Hold Rating for Zimmer Biomet Holdings (ZBH)

The medical device sector is evolving, driven by rising demand for precision technology in diagnostics. Therefore, it could be ideal to buy fundamentally solid medical device stocks Stryker Corp (SYK), Axogen (AXGN), and Zimmer Biomet Holdings (ZBH), which look poised for substantial growth. Read more… With an aging population and a rise in chronic health issues, medical technology innovations are rapidly becoming essential in healthcare, enabling quicker diagnoses and improved patient outcomes. The medical device industry is experiencing dynamic growth fueled by advancements in technology and increasing demand for innovative healthcare solutions.
Given this landscape, investors might consider investing in three fundamentally strong medical devices stocks, Stryker Corporation (<a href="https://stocknews.com/stock/SYK/">SYK</a>), Axogen, Inc. (<a href="https://stocknews.com/stock/AXGN/">AXGN</a>), and Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>), that are well-positioned for potential growth.
Medical device companies specializing in surgical robotics, imaging, diagnostics, and portable health monitoring devices are delivering innovative products that meet the rising demand for efficient and less invasive treatments. The <a href="https://blog.bccresearch.com/the-growing-market-for-elderly-and-disabled-assistive-devices">key market driver in this sector</a> is the aging population, rising awareness and accessibility, and a surge in technological advancements.
As per the <a href="https://www.medicaldevice-network.com/sponsored/ageing-in-the-digital-era-the-surge-of-medical-device-innovation-for-older-adults/">World Health Organization (WHO), the global population aged 60</a> and above will double to 2.1 billion by 2050. This demographic shift means the role of medical devices will be more crucial than at other times in history.
Healthcare providers and patients alike are prioritizing convenience and precision, pushing for technologies that aid in real-time monitoring and minimally invasive procedures. The <a href="https://www.advamed.org/medical-device-industry-facts/">United States is the largest medical device market in the world</a>, compromising over 40% of the global MedTech market, providing physicians and other healthcare providers with the best tools to diagnose and treat patients.
According to a KPMG report, the medical device industry is poised for steady growth, with global <a href="https://kpmg.com/us/en/articles/2023/medical-devices-2030.html">annual sales forecasted to reach nearly $800 billion by 2030</a>, with a rise of over 5% a year. Companies in this space benefit from long-term demand as healthcare spending remains resilient.
Now, let's take a closer look at the fundamentals of the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> stocks mentioned above, beginning with the third choice.
Stock #3: Stryker Corporation (<a href="https://stocknews.com/stock/SYK/">SYK</a>)
Stryker Corporation operates as a medical technology company. The company operates through two segments: MedSurg and Neurotechnology, and Orthopaedics and Spine. 
On October 1, SYK announced the completion of the <a href="https://www.investopedia.com/terms/a/acquisition.asp">acquisition</a> of its Vertos Medical Inc., a leader in interventional pain management solutions for chronic lower back pain caused by lumbar spinal stenosis. This acquisition enhances non-surgical solutions with minimal invasive wild procedures for SYK.   
On September 17, SYK announced that it completed its acquisition of care.ai, a privately held company specializing in delivering AI-assisted virtual care workflows, smart room technology, and ambient intelligence solutions. This acquisition should strengthen Stryker's growing healthcare IT offering and wirelessly connected medical device portfolio.
In the fiscal third quarter that ended on September 30, 2024, SYK's net sales increased 11.9% year-over-year to $5.49 billion. The company reported an operating income of $2.43 billion, indicating a 9.2% growth from the prior-year quarter.
SYK's adjusted net earnings came in at $1.11 billion, up 17.3% year-over-year, while its adjusted earnings per share grew 16.7% from the year-ago value to $2.87.
For the full year 2024, SYK expects organic net sales to be in the range of 9.5% to 10% and adjusted net earnings diluted per share to range from $12 to $12.10.
The consensus revenue estimate of $6.36 billion for the fiscal first quarter (ending December 2024) represents a 9.4% increase year-over-year. The consensus EPS estimate of $3.87 for the same quarter indicates an 11.9% improvement year-over-year. The company has an excellent surprise history; it surpassed the consensus revenue and EPS estimates in each of the trailing four quarters.
Moreover, SYK's revenue has grown at CAGRs of 9.7% and 8.6% over the past three and five years, respectively. In addition, its EBIT increased at 8.4% CAGR over the past three years.
Over the past year, the stock has surged 33.3%, closing the last trading session at $369.02.
SYK's stance is apparent in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has a B grade for Growth, Stability, and Sentiment. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
Among the 138 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry, it is ranked #46. <a href="https://stocknews.com/stock/SYK/">Click here</a> to see the additional SYK ratings (Value, Momentum, and Quality).
Stock #2: Axogen, Inc. (<a href="https://stocknews.com/stock/AXGN/">AXGN</a>)
AXGN develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company offers repair solutions for surgeons and healthcare providers. Its products include Avance nerve graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Axotouch Two-Point Discriminator, and Axoguard HA+ Nerve Protector.
On June 24, AXGN launched Avive+ Soft Tissue Matrix&#x2122;, which is used for a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. This launch is a new opportunity to improve patient outcomes after acute traumatic injury.
During the third quarter that ended on September 30, 2024, AXGN's revenue increased 17.9% year-over-year to $48.64 million. The company's gross profit amounted to $36.44 million, reflecting an increase of 14.9% from the prior-year quarter.
Its adjusted EBITDA of $6.49 million, indicating a 175.6% growth from the prior-year quarter. In addition, AXGN's adjusted net income amounted to $3.15 million and $0.07 per share, reflecting considerable increases year-over-year.
Looking ahead, AXGN anticipates annual revenue for fiscal year 2024 to fall between $182 million and $186 million. The company also projects gross margin to be in the range of 74% to 76%.
Analysts expect AXGN's revenue for the fiscal year (ending December 2024) to increase 16.1% year-over-year to $184.60 million.
Over the past three and five years, AXGN's revenue income grew at CAGRs of 9.9% and 12.5%, respectively, while its total assets grew at 3.8% CAGR over the past five years.
The stock has gained 290.1% over the past year and 170.4% over the past six months to close the last trading session at $15.33.
AXGN's POWR Ratings reflect its promising outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system.
AXGN has an A grade for Growth and B for Sentiment. It is ranked #35 in the Medical - Devices &amp; Equipment industry. <a href="https://stocknews.com/stock/AXGN/">Click here</a> to see the other ratings of AXGN for Value, Momentum, Stability, and Quality.
Stock #1: Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>)
ZBH is a global medical technology company that designs, manufactures, and markets orthopedic reconstructive products, like knee and hip products, S.E.T. products, and craniomaxillofacial and thoracic products.
On August 7, ZBH signed an agreement to acquire OrthoGrid Systems, Inc., a privately held medical technology company focused on AI-driven surgical guidance systems for total hip replacement. This acquisition will help ZBH address the challenges of orthopedic problems with innovative technology solutions.
For the third quarter of 2024, which ended on September 30, ZBH's total revenues increased 4% year-over-year to $1.82 billion. Its operating profit rose 4.8% from the year-ago value to $279.50 million. The company's adjusted net earnings stood at $353.20 million, up marginally year-over-year, while its adjusted EPS for the quarter increased 5.5% year-over-year to $1.74.
According to the company's financial guidance for fiscal year 2024, ZBH forecasts revenue between 3.5%-4%. The company also expects adjusted diluted EPS to be between $7.95 and $8.05.
Street expects ZBH's revenue for the fiscal fourth quarter (ending December 2024) to increase 3.9% year-over-year to $2.02 billion. Its EPS for the same period is expected to register a 4.3% growth from the prior year, settling at $2.30. In addition, it surpassed the consensus revenue and EPS estimates in each of the trailing four quarters, which is excellent.
ZBH's normalized net income has grown at CAGRs of 8.7% and 3.8% over the past three and five years, respectively. Likewise, the company's levered FCF has increased at a CAGR of 2.2% over the past five years.
ZBH's stock has surged 5.2% over the past month to close the last trading session at $110.17.
ZBH's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
It also has a B grade for Growth and Value. Within the same industry, it is ranked #17 out of 328 stocks. <a href="https://stocknews.com/stock/ZBH/">Click here</a> to see ZBH's ratings for Momentum, Stability, Sentiment, and Quality.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
SYK shares were trading at $369.10 per share on Thursday afternoon, up $0.08 (+0.02%). Year-to-date, SYK has gained 24.10%, versus a 26.40% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: ShreyaRathi</h2> <img src='https:/wp-content/uploads/2024/10/0.jpeg' style="float:left; padding:5px;width:125px;"><a href="https://stocknews.com/authors/?author=shreya-rathi">More...</a>The post <a href=https://stocknews.com/news/syk-zbh-axgn-3-medical-devices-stocks-poised-for-solid-growth/>3 Medical Devices Stocks Poised for Solid Growth</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Medical Devices Stocks Poised for Solid Growth

The health-tech industry's long-term growth is fueled by the growing need for cutting-edge technologies to address critical areas, as well as the demand for personalized medicine. Thus, it could be wise to invest in fundamentally solid health-tech stocks McKesson (MCK), Cardinal Health (CAH), and Zimmer Biomet (ZBH) poised for long-term growth. Keep reading... The integration of the latest technologies in the healthcare sector is continuously transforming its operations and contributing to its significant growth. The market is further poised for growth as it leverages the latest advancements like artificial intelligence (AI) and cloud computing.
Amid this backdrop, investors could consider investing in currently undervalued health-tech stocks McKesson Corporation (<a href="https://stocknews.com/stock/MCK/">MCK</a>), Cardinal Health, Inc. (<a href="https://stocknews.com/stock/CAH/">CAH</a>), and Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>) for long-term growth.
Technology is all pervasive, be it healthcare devices, pharmaceuticals, processes, or services; advanced technologies are marking strong strides and revolutionizing how activities have been performed traditionally. Also, amid rising chronic illnesses, an aging population, and a growing demand for personalized medicine, the healthcare industry's reliance on digital technology is expected to increase further.
The healthcare technology market is gaining rapid pace with recent trends like AI, cloud computing, and cutting-edge digital devices and technologies. The market is poised to exhibit growth at a notable <a href="https://www.thebusinessresearchcompany.com/report/healthcare-technology-global-market-report#:~:text=Healthcare%20Technology%20Market%20Size%202024,(CAGR)%20of%2018.0%25.">CAGR of 18.7%</a>, resulting in a market volume of $1.03 trillion by 2028, driven by a focus on preventive healthcare, remote patient monitoring, and healthcare infrastructure development.
In specific, adoption of Artificial Intelligence (AI) has emerged as the strongest and transformative force, pushing the healthcare sector to new advances. AI technology is presenting credible solutions for current drawbacks with its advantages like precision, efficiency, lower costs, and enhanced patient care.
The global AI in healthcare market is projected to <a href="https://www.marketsandmarkets.com/Market-Reports/artificial-intelligence-healthcare-market-54679303.html">reach $148.40 billion by 2029</a>, growing at a CAGR of 48.1%. The growth in the market is driven by the need for improved computing power, reduced healthcare costs, and the rising partnerships and collaborations among the healthcare market players.
Considering the conducive industry trends, let's delve deeper into the fundamentals of currently undervalued health-tech stocks such as MCK, CAH, and ZBH for long-term growth.
McKesson Corporation (<a href="https://stocknews.com/stock/MCK/">MCK</a>)
MCK is an international provider of healthcare services. The company operates in four segments: U.S. Pharmaceutical; Prescription Technology Solutions (RxTS); Medical-Surgical Solutions; and International. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products.
On September 5, MCK signed an agreement to sell its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm. The sale is part of MCK's enterprise strategy, enabling it to further focus and prioritize investments to grow its oncology and biopharma services platforms.
On August 26, MCK signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC, a business and administrative services organization, a leading physician-owned community oncology practice.
MCK purchased its controlling interest for approximately $2.49 billion in cash, which will represent approximately 70% ownership. The strategic acquisition marks an important step towards advancing community-based oncology care and enhances MCK's integrated oncology platform, Florida Cancer Specialists &amp; Research Institute, to join the US oncology network.
MCK's forward <a href="https://www.investopedia.com/terms/p/price-to-salesratio.asp">Price/Sales</a> of 0.22x is 94.5% lower than the industry average of 3.94x. Likewise, the stock's forward EV/EBIT multiple of 14.89 is 13% lower than the industry average of 17.11. Similarly, its forward non-GAAP P/E of 18.78x is 12.4% lower than the industry average of 21.44x.
During the second quarter that ended on September 30, 2024, MCK's revenues increased 21.3% year-over-year to $93.65 billion, and its adjusted gross profit increased 6.6% year-over-year to $3.25 billion. The company's adjusted earnings grew 8.8% from the year-ago value to $915 million, while its adjusted EPS came in at $7.07, up 13.5% year-over-year.
Street expects MCK's revenue and EPS for the third quarter (ending December 2024) to increase 18.5% and 9.4% year-over-year to $95.86 billion and $8.47, respectively. Moreover, the company topped the consensus EPS estimates in three of the trailing four quarters.
MCK's stock has increased 21.3% over the past month and 30.8% over the past year to close the last trading session at $615.59.
MCK's bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has a B grade for Growth, Value, and Sentiment. Within the <a href="https://stocknews.com/category/medical-services/">Medical - Services</a> industry, MCK is ranked #10 out of 64 stocks.
<a href="https://stocknews.com/stock/MCK/">Click here</a> to access additional ratings of MCK for Momentum, Quality, and Stability.
Cardinal Health, Inc. (<a href="https://stocknews.com/stock/CAH/">CAH</a>)
CAH operates as a healthcare services and products company internationally. It offers customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It operates in Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution segments.
On November 11, CAH entered into definitive agreements to acquire two companies to accelerate CAH's strategic growth areas and enhance patient care. This includes the acquisition of a majority stake in GI Alliance, the country's leading gastroenterology management services organization, to accelerate the multi-specialty growth strategy.
The acquisition of the Advanced Diabetes Supply Group, a leading national direct-to-patient provider of diabetes medical supplies, will also improve CAH's at-home Solutions growth strategy.
On October 29, CAH opened its new distribution center in Boylston, Massachusetts, supporting its U.S. Medical Products and Distribution business, which is nearly 317,000 square feet in size and will be available in early 2025. The facility provides modernized operations, expanded capacity, and specialized handling capabilities for products with strict storage requirements to healthcare customers.
In terms of forward non-GAAP P/E, CAH's 15.43x is 27.7% lower than the 21.33x industry average. Its 10.15x forward EV/EBITDA is 25.9% lower than the 13.69x industry average. Also, the company's forward Price/Sales of 0.13x is significantly lower than the 3.93x industry average.
CAH reported revenue of $52.28 billion for the first quarter that ended September 30, 2024. Its non-GAAP operating earnings grew 12.2% from the year-ago value to $625 million. The company's non-GAAP net earnings attributable to CAH came in at $460 million or $1.88 per common share, up 7% and 9.3% from the prior year's quarter, respectively.
The company raised its fiscal 2025 guidance range for non-GAAP EPS attributable to CAH to $7.75 to $7.90 from the previous range of $7.55 to $7.70. It also includes an update to the company's Pharmaceutical and Specialty Solutions segment profit outlook to 4% to 6% growth, from 1% to 3% growth.
Street expects CAH's EPS for the third quarter (ending March 2025) to increase 5.4% year-over-year to $2.19, and its EPS for the same quarter is expected to be $53.74 billion. Also, the company has topped the consensus EPS estimate in all four trailing quarters, which is remarkable.
Shares of CAH have surged 24.1% over the past six months and 15.9% over the past year to close the last trading session at $121.64.
CAH's POWR Ratings reflect its sound fundamentals. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
CAH has a B grade for Value. The stock is ranked #16 among the 64 stocks in the Medical - Services industry.
In addition to the POWR Ratings we've stated above, we also have CAH ratings for Sentiment, Momentum, Quality, Growth, and Stability. Get all CAH ratings <a href="https://stocknews.com/stock/CAH/">here</a>.
Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>)
ZBH operates as a medical technology company globally. The company designs, manufactures, and markets orthopedic reconstructive products, like knee and hip products and S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products.
On August 7, ZBH entered into an agreement to acquire OrthoGrid Systems, Inc., a privately held medical technology company focused on AI-driven surgical guidance systems for total hip replacement. The strategic acquisition aligns well with ZBH's operations and will help it address the challenges of orthopedic problems with innovative technology solutions.
In terms of forward Price/Book, ZBH's 1.66x is 43.1% lower than the 2.92x industry average. Its forward EV/EBITDA of 10.66x is 22% lower than the industry average of 13.66x. Also, the company's forward Price/Sales of 2.84x is 28% lower than the 3.94x industry average.
During the third quarter of 2024, which ended September 30, ZBH's total revenues increased 4% year-over-year to $1.82 billion. Its adjusted operating profit rose 3.5% from the year-ago value to $480.20 million. Adjusted net earnings of ZBH and EPS came in at $353.20 million and $1.74, up 1.9% and 5.5% year-over-year, respectively.
Furthermore, the company's free cash flow rose 64.3% from the prior year's quarter to $310 million.
As per the company's updated guidance for fiscal 2024, ZBH projects reported revenue change between 3.5% - 4%. It also expects adjusted EPS in the range of $7.95 to $8.05.
Analysts expect ZBH's revenue for the fourth quarter (ending December 2024) to grow 3.9% year-over-year to $2.02 billion and its EPS for the same period is expected to increase 4.3% year-over-year to $2.30. Furthermore, the company surpassed the consensus EPS and revenue estimates in each of the trailing four quarters.
ZBH's shares have gained 3.5% over the past year to close the last trading session at $109.46.
ZBH's sound fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has a B grade for Value and Growth. Within the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> industry, ZBH is ranked #18 out of 137 stocks.
In addition to the POWR Ratings we've stated above, we also have ZBH ratings for Stability, Momentum, Quality, and Sentiment. Get all ZBH ratings <a href="https://stocknews.com/stock/ZBH/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>
&nbsp;

<hr />
MCK shares were unchanged in after-hours trading Tuesday. Year-to-date, MCK has gained 34.03%, versus a 26.77% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/mck-cah-zbh-3-undervalued-health-tech-stocks-to-buy-for-long-term-growth/>3 Undervalued Health-Tech Stocks to Buy for Long-Term Growth</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Undervalued Health-Tech Stocks to Buy for Long-Term Growth

Zimmer Biomet (ZBH) announced a partnership with Arnold Schwarzenegger, who will take on the newly established role of Chief Movement Officer. In t...

Comments

Zimmer Biomet Holdings

Actualités

Dernières nouvelles pour Zimmer Biomet Holdings (NYSE:ZBH) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL